|
Pivekimab Sunirine Clinical Trials
1 actively recruiting trial across 1 location
No change since March 2026
Also known as: Anti-CD123 ADC IMGN632, Antibody-drug Conjugate IMGN632, CD123-targeted ADC IMGN632, IMGN 632, IMGN-632 +1 more
Palo Alto, California1 trial
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lucile Packard Children's Hospital /ID# 276015
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.